```html

Uraemic Neuropathy – A Comprehensive Medical Guide

Overview

Uraemic neuropathy (also spelled uremic neuropathy) is a type of peripheral nerve disorder that occurs in people with advanced chronic kidney disease (CKD) or end‑stage renal disease (ESRD) when toxic metabolites accumulate in the blood because the kidneys can no longer filter them efficiently. The condition is characterized by a gradual loss of nerve function, most commonly affecting the legs and feet, but it may involve the hands, arms, and even autonomic nerves that control internal organ functions.

​Who it affects: The condition is almost exclusively seen in adults with CKD stage 4–5 (glomerular filtration rate <30 mL/min/1.73 m²) or those on long‑term dialysis. It is rare in children because pediatric CKD progresses more slowly and is more likely to be managed with transplantation.

Prevalence: Epidemiological studies estimate that 30–40 % of patients on maintenance hemodialysis develop clinically significant peripheral neuropathy, while up to 60 % may have subclinical abnormalities detectable by nerve‑conduction studies.<sup>1</sup> The prevalence rises sharply after 5–7 years of dialysis.

Symptoms

Symptoms evolve slowly and may be subtle at first. The most common pattern is a “stocking‑glove” distribution—affecting the feet and hands first.

Sensory symptoms

• Paresthesias: Tingling, “pins‑and‑needles,” or buzzing sensations, usually beginning in the toes and progressing upward.
• Numbness: Decreased ability to feel light touch, temperature, or vibration; patients may “walk on air” and not notice injuries.
• Allodynia: Pain from stimuli that are normally non‑painful (e.g., light rubbing of the skin).
• Hyperalgesia: Exaggerated response to painful stimuli.

Motor symptoms

• Weakness: Distal muscle weakness, especially in the foot extensors and intrinsic hand muscles, leading to difficulty fastening shoes or buttoning clothes.
• Atrophy: Visible wasting of the thenar and hypothenar eminences in the hand or the intrinsic foot muscles.
• Loss of coordination: Unsteady gait, frequent tripping, or inability to perform fine motor tasks.

Autonomic symptoms

• Orthostatic hypotension: Dizziness or light‑headedness on standing due to impaired sympathetic tone.
• Gastro‑intestinal dysmotility: Constipation, bloating, or gastroparesis.
• Urinary retention or incontinence: Rare but documented in severe cases.
• Sweating abnormalities: Either excessive sweating (hyperhidrosis) or anhidrosis.

Other associated features

• Pruritus (itching) unrelated to skin dryness.
• Muscle cramps, especially at night.
• Reduced tendon reflexes (often absent at the ankles).

Causes and Risk Factors

Uraemic neuropathy is not caused by a single toxin; rather, it results from a complex milieu of metabolic derangements that accompany severe renal failure.

Primary pathogenic mechanisms

• Retention of uremic toxins: Middle‑molecule toxins such as guanidine compounds, β‑2 microglobulin, and advanced glycation end‑products (AGEs) directly damage nerve axons and Schwann cells.<sup>2</sup>
• Metabolic acidosis: Low plasma bicarbonate leads to intracellular calcium influx, impairing nerve conduction.
• Electrolyte disturbances: Hyper‑phosphatemia, hypo‑magnesemia, and fluctuations in calcium can destabilize neuronal membranes.
• Oxidative stress & inflammation: Elevated cytokines (IL‑6, TNF‑α) and reactive oxygen species cause demyelination.
• Secondary hyperparathyroidism: Excess parathyroid hormone (PTH) can cause calcium‑phosphate deposition in peripheral nerves.

Risk factors

• Duration of dialysis >5 years (risk ↑ by ~2.5‑fold).<sup>3</sup>
• Older age (>60 years) – nerves have reduced regenerative capacity.
• Concurrent diabetes mellitus – synergistic effect with diabetic neuropathy.
• High serum β‑2 microglobulin (>5 mg/L) – predicts severity.
• Poor nutritional status (low albumin <3.5 g/dL) – impairs nerve repair.
• Inadequate dialysis clearance (Kt/V <1.2 for hemodialysis).

Diagnosis

Because symptoms overlap with diabetic and other neuropathies, a systematic approach is essential.

Clinical assessment

• Detailed history focusing on CKD stage, dialysis vintage, and symptom chronology.
• Neurological examination: sensory testing (pinprick, vibration), motor strength grading, reflex assessment, gait analysis.

Electrodiagnostic studies

• Nerve‑conduction studies (NCS): Show reduced amplitude and slowed conduction velocity, predominantly in sensory fibers.
• Electromyography (EMG): Detects chronic denervation changes in distal muscles.

Laboratory tests

• Renal function panel (creatinine, eGFR).
• Serum urea, β‑2 microglobulin, PTH, calcium‑phosphate product.
• Electrolytes (Mg²⁺, Ca²⁺, K⁺).
• Inflammatory markers (CRP, IL‑6) when available.

Imaging (occasionally)

• MRI of the lumbar spine if radiculopathy is suspected.
• Ultrasound of peripheral nerves to rule out compressive neuropathies.

Exclusion of other causes

Screen for diabetes (HbA1c), vitamin B12 deficiency, hypothyroidism, connective‑tissue disease, and exposure to neurotoxic drugs.

Treatment Options

Management combines removal of uremic toxins, symptom control, and measures to protect nerve health.

Optimizing renal replacement therapy

• High‑efficiency hemodialysis: Increasing Kt/V (>1.4), using high‑flux membranes, and extending session length (≥4 hours) can lower toxin load.<sup>4</sup>
• Hemodiafiltration (HDF): Provides superior clearance of middle‑molecule toxins such as β‑2 microglobulin.
• Peritoneal dialysis (PD): May be preferable in patients with severe neuropathy because of continuous toxin removal, but evidence is mixed.
• Renal transplantation: Reverses uraemic neuropathy in up to 70 % of patients within 12 months, especially if performed before irreversible axonal loss.<sup>5</sup>

Pharmacologic symptom control

• Neuropathic pain agents:
  • Gabapentin (starting 300 mg day⁻¹, titrate to 900–1800 mg) – consider dose reduction in advanced CKD.
  • Pren​antal (starting 25 mg day⁻¹, titrate to 150 mg) – monitor for sedation.
  • Duloxetine (60 mg day⁻¹) – contraindicated if eGFR <30 mL/min/1.73 m².
• Topical agents: 5 % lidocaine patches or capsaicin 8 % patches for focal pain.
• Adjuncts: Alpha‑lipoic acid 600 mg day⁻¹ (antioxidant) has shown modest benefit in small trials; discuss with nephrologist.

Correcting metabolic contributors

• Acidosis: Oral sodium bicarbonate (0.5–1 g day⁻¹) to maintain serum bicarbonate 22–26 mmol/L.
• Hyper‑phosphatemia: Non‑calcium phosphate binders (sevelamer, lanthanum).
• Hypo‑magnesemia: Mg‑oxide or Mg‑hydroxide supplementation.
• Vitamin D and calcimimetics to control secondary hyperparathyroidism.

Physical and rehabilitative therapy

• Strengthening and balance exercises (tai‑chi, supervised physiotherapy) to reduce falls.
• Occupational therapy for hand dexterity—adaptive devices for buttoning, writing.

Emerging therapies (research stage)

• Intravenous immunoglobulin (IVIG) for immune‑mediated nerve injury—limited data.
• Targeted removal of specific toxins using adsorptive cartridges (e.g., MARS®) in selected centers.

Living with Uraemic Neuropathy

Adapting daily life can improve safety, independence, and quality of life.

Foot care

• Inspect feet daily for cuts, blisters, or redness—use a handheld mirror or ask a caregiver.
• Wear well‑fitting, moisture‑wicking socks and shoes with a wide toe box.
• Keep nails trimmed straight; consider a podiatrist for routine care.
• Promptly treat any wound; even minor skin breaks can lead to infection and, in dialysis patients, amputations.

Safety modifications

• Install grab bars in the bathroom and non‑slip mats.
• Use a walking aid (cane or walker) if gait is unstable.
• Ensure adequate lighting, especially at night; night‑lights can prevent falls.

Nutrition and hydration

• Maintain protein intake as prescribed by the renal dietitian (usually 0.8–1.0 g/kg). Adequate protein supports nerve repair.
• Stay hydrated within fluid‑restriction limits to avoid exacerbating edema, which can further impair circulation.
• Include omega‑3 fatty acid–rich foods (e.g., low‑phosphorus fish) as they have anti‑inflammatory properties.

Exercise

• Low‑impact aerobic activity (walking, stationary cycling) 3–5 times per week improves peripheral circulation.
• Resistance training twice weekly helps preserve muscle mass.
• Always discuss new exercise plans with your nephrologist and physical therapist.

Medication adherence

• Keep a medication list; use pill organizers to avoid missed doses.
• Report any new or worsening pain to your care team—doses often need adjustment as kidney function changes.

Psychosocial support

• Chronic neuropathic pain can lead to depression or anxiety; consider counseling or support groups.
• Mind‑body techniques (guided imagery, relaxation breathing) have modest benefit.

Prevention

While uraemic neuropathy cannot be entirely prevented in patients with advanced CKD, several strategies can delay onset or reduce severity.

• Early referral to a nephrologist: Timely initiation of optimal dialysis or transplantation planning.
• Maintain target dialysis adequacy: Aim for Kt/V ≥1.4 (hemodialysis) and consider high‑flux membranes.
• Control metabolic disturbances: Treat acidosis, hyperphosphatemia, and secondary hyperparathyroidism aggressively.
• Blood pressure control: Keep systolic BP <130 mmHg to protect microvascular health.
• Manage diabetes rigorously: HbA1c <7 % where feasible; use agents with low hypoglycemia risk.
• Avoid nephrotoxic drugs: Limit aminoglycosides, NSAIDs, and contrast agents whenever possible.
• Nutrition: Adequate intake of vitamins B6, B12, and folate; supplementation under dietitian guidance.
• Smoking cessation: Smoking worsens vascular and nerve injury.

Complications

If left untreated or poorly managed, uraemic neuropathy can lead to serious sequelae.

• Foot ulcers and infections: Up to 30 % of dialysis patients develop foot problems; infections may progress to osteomyelitis or require amputation.
• Falls and fractures: Impaired sensation and orthostatic hypotension raise fall risk; fractures further decrease mobility.
• Severe chronic pain: Can impair sleep, nutrition, and mood, increasing hospitalization rates.
• Autonomic dysfunction: May precipitate sudden blood pressure drops, arrhythmias, or gastrointestinal ileus.
• Reduced dialysis efficacy: Pain or discomfort can limit patient tolerance for longer or more frequent sessions.

When to Seek Emergency Care

References

1. National Kidney Foundation – Uremic Neuropathy
2. Gutzeit G, et al. “Uremic toxins and peripheral neuropathy.” *Kidney Int* 2015.
3. Cleveland Clinic – Uremic Neuropathy
4. Wang X, et al. “High‑flux hemodialysis improves peripheral nerve function.” *Nephrol Dial Transplant* 2013.
5. Mayo Clinic – Uremic Neuropathy Diagnosis & Treatment

```